SAN FRANCISCO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Elanco Animal Health (NYSE: ELAN) is facing a securities class action lawsuit alleging the company misled investors about the safety and regulatory path of its new dermatology drug, Zenrelia. Hagens Berman urges Elanco investors who suffered substantial losses to submit your losses now. Class Period: Nov. 7, 2023 – June 26, 2024 Lead Plaintiff Deadline: Dec. 6, 2024 Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com 844-916-0895 ...